Back to results

WithdrawnPhase 3

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

NCT04287179

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novo Nordisk Investigational Site

Buena Park, California, United States

+24 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2020-03-09
Enrollment: 0 participants
Sponsor: Novo Nordisk A/S
Purpose: treatment

Locations (25)

Novo Nordisk Investigational SiteBuena Park, California, United States
Novo Nordisk Investigational SiteFresno, California, United States
Novo Nordisk Investigational SiteSan Jose, California, United States
Novo Nordisk Investigational SiteWalnut Creek, California, United States
Novo Nordisk Investigational SiteWaterbury, Connecticut, United States
Novo Nordisk Investigational SiteHonolulu, Hawaii, United States
Novo Nordisk Investigational SiteIdaho Falls, Idaho, United States
Novo Nordisk Investigational SiteIndianapolis, Indiana, United States
Novo Nordisk Investigational SiteTroy, Michigan, United States
Novo Nordisk Investigational SiteAlbany, New York, United States
Novo Nordisk Investigational SiteWest Seneca, New York, United States
Novo Nordisk Investigational SiteDallas, Texas, United States
Novo Nordisk Investigational SiteRound Rock, Texas, United States
Novo Nordisk Investigational SiteSugar Land, Texas, United States
Novo Nordisk Investigational SiteGraz, Austria
Novo Nordisk Investigational SiteStockerau, Austria
Novo Nordisk Investigational SiteVienna, Austria
Novo Nordisk Investigational SiteVienna, Austria
Novo Nordisk Investigational SiteJyväskylä, Finland
Novo Nordisk Investigational SiteKuopio, Finland
Novo Nordisk Investigational SiteLahti, Finland
Novo Nordisk Investigational SiteRaisio, Finland
Novo Nordisk Investigational SiteSeinäjoki, Finland
Novo Nordisk Investigational SiteGothenburg, Sweden
Novo Nordisk Investigational SiteMalmö, Sweden

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes — TrialFind